Login Register Cart 0
Generic placeholder image

Current Topics in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1568-0266
ISSN (Online): 1873-4294

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspectives in Medicinal Chemistry

Perspectives in the Treatment of Heart Failure with Preserved Ejection Fraction: From Drugs to Devices

Author(s): Marko Banovic*, Milica Bojanic and Serge D. Nikolic

Volume 20, Issue 4, 2020

Page: [266 - 271] Pages: 6

DOI: 10.2174/156802662004200304124916

« Previous Next »
[1]
Lourenco, A.P.; Leite-Moreira, A.F.; Balligand, J-L. An integrative translational approach to studyheart failure with preserved ejection fraction: a position paper from the working group on myocardial Function of the European Society of Cardiology. Eur. J. Heart Fail., 2018, 20, 216-227.
[2]
Nedeljkovic, I.; Banovic, M.; Stepanovic, J.; Giga, V.; Djordjevic-Dikic, A.; Trifunovic, D.; Nedeljkovic, M.; Petrovic, M.; Dobric, M.; Dikic, N.; Zlatar, M.; Beleslin, B. The combined exercise stress echocardiography and cardiopulmonary exercise test for identification of masked heart failure with preserved ejection fraction in patients with hypertension. Eur. J. Prev. Cardiol., 2016, 23(1), 71-77.
[http://dx.doi.org/10.1177/2047487315604836] [PMID: 26358991]
[3]
Savarese, G.; Lund, L.H. Global public health burden of heart failure. Card. Fail. Rev., 2017, 3(1), 7-11.
[http://dx.doi.org/10.15420/cfr.2016:25:2] [PMID: 28785469]
[4]
Runte, KE.; Bell, SP.; Selby, DE. Relaxation and the role of calcium in iso-lated contracting myocardium from patients with hypertensive heart disease and heart failure with preserved ejection fraction. Circ Heart Fail, 2017, 10(8) e004311
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.117.004311] [PMID: 2878468]
[5]
Marc, A. Pfeffer, Amil M. Shah, Barry A. Borlaug. Heart Failure With Preserved Ejection Fraction In Perspective. Circ. Res., 2019, 124, 1598-1617.
[http://dx.doi.org/10.1161/CIRCRESAHA.119.313572]
[6]
Tschöpe, C.; Birner, C.; Böhm, M.; Bruder, O.; Frantz, S.; Luchner, A.; Maier, L.; Störk, S.; Kherad, B.; Laufs, U. Heart failure with preserved ejection fraction: current management and future strategies: Expert opinion on the behalf of the Nucleus of the “Heart Failure Working Group” of the German Society of Cardiology (DKG). Clin. Res. Cardiol., 2018, 107(1), 1-19.
[http://dx.doi.org/10.1007/s00392-017-1170-6] [PMID: 29018938]
[7]
Davis, B.R.; Kostis, J.B.; Simpson, L.M.; Black, H.R.; Cushman, W.C.; Einhorn, P.T.; Farber, M.A.; Ford, C.E.; Levy, D.; Massie, B.M.; Nawaz, S. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation, 2008, 118(22), 2259-2267.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.762229] [PMID: 19001024]
[8]
Paulus, W.J.; Tschöpe, C.; Sanderson, J.E.; Rusconi, C.; Flachskampf, F.A.; Rademakers, F.E.; Marino, P.; Smiseth, O.A.; De Keulenaer, G.; Leite-Moreira, A.F.; Borbély, A.; Edes, I.; Handoko, M.L.; Heymans, S.; Pezzali, N.; Pieske, B.; Dickstein, K.; Fraser, A.G.; Brutsaert, D.L. How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur. Heart J., 2007, 28(20), 2539-2550.
[http://dx.doi.org/10.1093/eurheartj/ehm037] [PMID: 17428822]
[9]
Tschöpe, C.; Lam, C.S. Diastolic heart failure: What we still don’t know. Looking for new concepts, diagnostic approaches, and the role of comorbidities. Herz, 2012, 37(8), 875-879.
[http://dx.doi.org/10.1007/s00059-012-3719-5] [PMID: 23179053]
[10]
Lam, C.S.P.; Voors, A.A.; de Boer, R.A.; Solomon, S.D.; van Veldhuisen, D.J. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur. Heart J., 2018, 39(30), 2780-2792.
[http://dx.doi.org/10.1093/eurheartj/ehy301] [PMID: 29905796]
[11]
Cleland, J.G.; Tendera, M.; Adamus, J.; Freemantle, N.; Polonski, L.; Taylor, J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur. Heart J., 2006, 27(19), 2338-2345.
[http://dx.doi.org/10.1093/eurheartj/ehl250] [PMID: 16963472]
[12]
Borlaug, B.A. The pathophysiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol., 2014, 11(9), 507-515.
[http://dx.doi.org/10.1038/nrcardio.2014.83] [PMID: 24958077]
[13]
Abraham, W.T.; Stevenson, L.W.; Bourge, R.C.; Lindenfeld, J.A.; Bauman, J.G.; Adamson, P.B. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet, 2016, 387(10017), 453-461.
[http://dx.doi.org/10.1016/S0140-6736(15)00723-0] [PMID: 26560249]
[14]
Yusuf, S.; Pfeffer, M.A.; Swedberg, K.; Granger, C.B.; Held, P.; McMurray, J.J.; Michelson, E.L.; Olofsson, B.; Ostergren, J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, 2003, 362(9386), 777-781.
[http://dx.doi.org/10.1016/S0140-6736(03)14285-7] [PMID: 13678871]
[15]
Pitt, B.; Pfeffer, M.A.; Assmann, S.F.; Boineau, R.; Anand, I.S.; Claggett, B.; Clausell, N.; Desai, A.S.; Diaz, R.; Fleg, J.L.; Gordeev, I.; Harty, B.; Heitner, J.F.; Kenwood, C.T.; Lewis, E.F.; O’Meara, E.; Probstfield, J.L.; Shaburishvili, T.; Shah, S.J.; Solomon, S.D.; Sweitzer, N.K.; Yang, S.; McKinlay, S.M. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med., 2014, 370(15), 1383-1392.
[http://dx.doi.org/10.1056/NEJMoa1313731] [PMID: 24716680]
[16]
Farasat, S.M.; Bolger, D.T.; Shetty, V.; Menachery, E.P.; Gerstenblith, G.; Kasper, E.K.; Najjar, S.S. Effect of Beta-blocker therapy on rehospitalization rates in women versus men with heart failure and preserved ejection fraction. Am. J. Cardiol., 2010, 105(2), 229-234.
[http://dx.doi.org/10.1016/j.amjcard.2009.09.008] [PMID: 20102924]
[17]
Cleland, J.G.F.; Bunting, K.V.; Flather, M.D.; Altman, D.G.; Holmes, J.; Coats, A.J.S.; Manzano, L.; McMurray, J.J.V.; Ruschitzka, F.; van Veldhuisen, D.J.; von Lueder, T.G.; Böhm, M.; Andersson, B.; Kjekshus, J.; Packer, M.; Rigby, A.S.; Rosano, G.; Wedel, H.; Hjalmarson, Å.; Wikstrand, J.; Kotecha, D. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur. Heart J., 2018, 39(1), 26-35.
[http://dx.doi.org/10.1093/eurheartj/ehx564] [PMID: 29040525]
[18]
Ramasubbu, K.; Estep, J.; White, DL.; Deswal, A.; Mann, DL. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J. Am. Coll. Cardiol., 2008, 51(4), 415-426.
[http://dx.doi.org/10.1016/j.jacc.2007.10.009] [PMID: 18222351]
[19]
Antoniades, C.; Bakogiannis, C.; Leeson, P.; Guzik, T.J.; Zhang, M.H.; Tousoulis, D.; Antonopoulos, A.S.; Demosthenous, M.; Marinou, K.; Hale, A.; Paschalis, A.; Psarros, C.; Triantafyllou, C.; Bendall, J.; Casadei, B.; Stefanadis, C.; Channon, K.M. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation, 2011, 124(3), 335-345.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.985150] [PMID: 21730307]
[20]
Shah, S.J.; Kitzman, D.W.; Borlaug, B.A.; van Heerebeek, L.; Zile, M.R.; Kass, D.A.; Paulus, W.J. Phenotype-specific treatment of heart failure with preserved ejection fraction. Circulation, 2016, 134(1), 73-90.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.021884] [PMID: 27358439]
[21]
Paulus, W.J.; Tschöpe, C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol., 2013, 62(4), 263-271.
[http://dx.doi.org/10.1016/j.jacc.2013.02.092] [PMID: 23684677]
[22]
Redfield, M.M.; Anstrom, K.J.; Levine, J.A.; Koepp, G.A.; Borlaug, B.A.; Chen, H.H.; LeWinter, M.M.; Joseph, S.M.; Shah, S.J.; Semigran, M.J.; Felker, G.M.; Cole, R.T.; Reeves, G.R.; Tedford, R.J.; Tang, W.H.; McNulty, S.E.; Velazquez, E.J.; Shah, M.R.; Braunwald, E. Isosorbide mononitrate in heart failure with preserved ejection fraction. N. Engl. J. Med., 2015, 373(24), 2314-2324.
[http://dx.doi.org/10.1056/NEJMoa1510774] [PMID: 26549714]
[23]
Thomas, G.R.; DiFabio, J.M.; Gori, T.; Parker, J.D. Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. J. Am. Coll. Cardiol., 2007, 49(12), 1289-1295.
[http://dx.doi.org/10.1016/j.jacc.2006.10.074] [PMID: 17394960]
[24]
Oelze, M.; Knorr, M.; Kröller-Schön, S.; Kossmann, S.; Gottschlich, A.; Rümmler, R.; Schuff, A.; Daub, S.; Doppler, C.; Kleinert, H.; Gori, T.; Daiber, A.; Münzel, T. Chronic therapy with isosorbide-5-mononitrate causes endothelial dysfunction, oxidative stress, and a marked increase in vascular endothelin-1 expression. Eur. Heart J., 2013, 34(41), 3206-3216.
[http://dx.doi.org/10.1093/eurheartj/ehs100] [PMID: 22555214]
[25]
McMurray, J.J.; Packer, M.; Desai, A.S.; Gong, J.; Lefkowitz, M.P.; Rizkala, A.R.; Rouleau, J.L.; Shi, V.C.; Solomon, S.D.; Swedberg, K.; Zile, M.R. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med., 2014, 371(11), 993-1004.
[http://dx.doi.org/10.1056/NEJMoa1409077] [PMID: 25176015]
[26]
Burke, R.M.; Lighthouse, J.K.; Mickelsen, D.M.; Small, E.M. Sacubitril/valsartan decreases cardiac fibrosis in left ventricle pressure overload by restoring PKG signaling in cardiac fibroblasts. Circ Heart Fail, 2019, 12(4) e005565
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.118.005565] [PMID: 30998392 ]
[27]
Solomon, S.D.; McMurray, J.J.V.; Anand, I.S.; Ge, J.; Lam, C.S.P.; Maggioni, A.P.; Martinez, F.; Packer, M.; Pfeffer, M.A.; Pieske, B.; Redfield, M.M.; Rouleau, J.L.; van Veldhuisen, D.J.; Zannad, F.; Zile, M.R.; Desai, A.S.; Claggett, B.; Jhund, P.S.; Boytsov, S.A.; Comin-Colet, J.; Cleland, J.; Düngen, H.D.; Goncalvesova, E.; Katova, T.; Kerr Saraiva, J.F.; Lelonek, M.; Merkely, B.; Senni, M.; Shah, S.J.; Zhou, J.; Rizkala, A.R.; Gong, J.; Shi, V.C.; Lefkowitz, M.P. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N. Engl. J. Med., 2019, 381(17), 1609-1620.
[http://dx.doi.org/10.1056/NEJMoa1908655] [PMID: 31475794]
[28]
Lee, D.I.; Kass, D.A. Phosphodiesterases and cyclic GMP regulation in heart muscle. Physiology (Bethesda), 2012, 27(4), 248-258.
[http://dx.doi.org/10.1152/physiol.00011.2012] [PMID: 22875455]
[29]
Kirk, J.A.; Holewinski, R.J.; Crowgey, E.L.; Van Eyk, J.E. Protein kinase G signaling in cardiac pathophysiology: Impact of proteomics on clinical trials. Proteomics, 2016, 16(5), 894-905.
[http://dx.doi.org/10.1002/pmic.201500401] [PMID: 26670943]
[30]
Stasch, J.P.; Pacher, P.; Evgenov, O.V. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation, 2011, 123(20), 2263-2273.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.981738] [PMID: 21606405]
[31]
Pieske, B.; Maggioni, A.P.; Lam, C.S.P.; Pieske-Kraigher, E.; Filippatos, G.; Butler, J.; Ponikowski, P.; Shah, S.J.; Solomon, S.D.; Scalise, A.V.; Mueller, K.; Roessig, L.; Gheorghiade, M. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur. Heart J., 2017, 38(15), 1119-1127.
[http://dx.doi.org/10.1093/eurheartj/ehw593] [PMID: 2836934]
[32]
Banović, M.D.; Ristić, A.D. The role of mitochondrial dysfunction in heart failure and potential therapeutic targets. Curr. Pharm. Des., 2016, 22(31), 4752-4762.
[http://dx.doi.org/10.2174/1381612822666160614081853] [PMID: 27306092]
[33]
Gude, E.; Fiane, A. A novel rotary blood pump for HFpEF. J. Heart Lung Transplant., 2019, 38(4), S342.
[http://dx.doi.org/10.1016/j.healun.2019.01.868]
[34]
Georgakopoulos, D.; Little, W.C.; Abraham, W.T.; Weaver, F.A.; Zile, M.R. Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. J. Card. Fail., 2011, 17(2), 167-178.
[http://dx.doi.org/10.1016/j.cardfail.2010.09.004] [PMID: 21300307]
[35]
Costanzo, M.R.; Goldberg, L.; McKane, S. Effects of phrenic nerve stimulation in subjects with central sleep apnoea and heart failure with reduced, mid-range, and preserved ejection fraction: findings from the remede system pivotal trial 2019.
[36]
Vaduganathan, M.; DeFilippis, E.M.; Fonarow, G.C.; Butler, J.; Mehra, M.R. Postmarketing adverse events related to the cardioMEMS HF system. JAMA Cardiol., 2017, 2(11), 1277-1279.
[http://dx.doi.org/10.1001/jamacardio.2017.3791] [PMID: 28975249]
[37]
Tschöpe, C.; Kherad, B.; Klein, O.; Lipp, A.; Blaschke, F.; Gutterman, D.; Burkhoff, D.; Hamdani, N.; Spillmann, F.; Van Linthout, S. Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond. Eur. J. Heart Fail., 2019, 21(1), 14-22.
[http://dx.doi.org/10.1002/ejhf.1349] [PMID: 30485591]
[38]
Feld, Y.; Dubi, S.; Reisner, Y.; Schwammenthal, E.; Shofti, R.; Pinhasi, A.; Carasso, S.; Elami, A. Energy transfer from systole to diastole: a novel device-based approach for the treatment of diastolic heart failure. Acute Card. Care, 2011, 13(4), 232-242.
[http://dx.doi.org/10.3109/17482941.2011.634012] [PMID: 22142202]
[39]
Banovic, M.; Loncar, Z.; Behfar, A. Endpoints in stem cell trials in ischemic heart failure. Stem Cell Res. Ther., 2015, 29(6), 159.
[http://dx.doi.org/10.1186/s13287-015-0143-9]

Rights & Permissions Print Cite
Article Metrics
12
2
© 2024 Bentham Science Publishers | Privacy Policy